Molecular Partners latest IPO failure, others hang in balance
Molecular Partners became the latest victim of the recent bout of volatility in Europe’s equity capital markets, as the Swiss biotech firm announced on Tuesday that it would have to put its projected listing on hold. Further deals could yet fall, bankers said.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts